Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2010 - 2026)

Jazz Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 22.99% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 21.4% YoY), while the FY2025 annual figure was $1.3 billion, down 4.48% from the prior year.
• Free Cash Flow for Q1 2026 stood at $331.0 million, down from $1.2 billion in the prior quarter.
• The five-year high for Free Cash Flow was $1.2 billion in Q4 2025, with the low at -$382.6 million in Q3 2025.
• The 5-year median for Free Cash Flow is $316.9 million (2023), against an average of $313.3 million.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 629.43% in 2022, then plunged 198.63% in 2025.
• Jazz Pharmaceuticals' Free Cash Flow stood at $337.6 million in 2022, then plunged by 46.33% to $181.2 million in 2023, then jumped by 112.64% to $385.3 million in 2024, then surged by 201.54% to $1.2 billion in 2025, then tumbled by 71.51% to $331.0 million in 2026.
• Business Quant data shows JAZZ's Free Cash Flow at $331.0 million in Q1 2026, $1.2 billion in Q4 2025, and -$382.6 million in Q3 2025.